Value
5.6/10data confidence 100%| Component | Sub-score |
|---|---|
| P/E | 3.2 |
| P/S | 7.7 |
| EV/EBITDA | 0.2 |
| Fwd P/E | 6.4 |
| PEG | 5.2 |
| Analyst target | 9.0 |
- ▸Forward P/E: 20.3x
- ▸PEG: 1.44
PODD · Why this verdict
Why Insulet (PODD) is rated BUY WAIT
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictBUY WAIT
Overall score6.8/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
Insulet Corporation combines best-in-class growth of 34% year-over-year with a perfect four-quarter earnings beat streak and a strong economic moat, but its current technical downtrend and failed momentum gate create a timing headwind that must resolve before the quality-growth combination can be fully valued.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Insulet has beaten consensus earnings in every one of the last four quarters with an average positive surprise of 15%, and revenue grew 34% year-over-year, indicating that operational execution is consistent and the growth runway remains intact. Earnings | Revenue growth remains above 25% and quarterly earnings beats continue in at least 3 of the next 4 quarters over the next 12 months. | ↑Improving |
| CounterHigh-growth medical device companies frequently face reimbursement headwinds and competitive entrants; sustaining 34% growth at scale becomes increasingly difficult. | ||
The business scores a perfect 9/9 Piotroski F-Score and meets the Rule of 40 threshold at 43, while the moat score of 8.2/10 signals durable competitive advantages that support high returns on capital over time. Quality breakdown | Gross margin holds above current levels and Piotroski F-Score stays at 8 or above over the next four reporting periods. | →Stable |
| CounterA significant share of quality advantage derives from the Omnipod platform concentration, meaning any regulatory setback or competitive substitute directly impairs the moat. | ||
Although MACD is showing improvement and RSI stands at 45, the stock remains below its 200-day moving average with the moving average slope at negative 8.0% per 30 days, meaning the technical recovery thesis requires a confirmed breakout above resistance to validate. Momentum breakdown | The stock rises above its 200-day moving average and momentum score rises above 5.0 within the next 6 months. | ↓Deteriorating |
| CounterDeath cross conditions combined with falling on-balance volume suggest that institutional sellers may continue to dominate price action, keeping momentum weak for an extended period. | ||
Reliance on the single Omnipod product platform and sole-sourced components represents a structural risk where disruption to either the product line or the supply chain could materially impair revenue with limited near-term substitution options. Bear case | The company discloses supply chain diversification progress or new product-line contributions exceed 10% of revenue within 12 months. | ↓Deteriorating |
| CounterPlatform concentration has not historically harmed Insulet; the Omnipod system's clinical differentiation and installed base create switching costs that offset concentration risk. | ||
Insulet has beaten consensus earnings in every one of the last four quarters with an average positive surprise of 15%, and revenue grew 34% year-over-year, indicating that operational execution is consistent and the growth runway remains intact.
↑ImprovingEarnings
- Expectation
- Revenue growth remains above 25% and quarterly earnings beats continue in at least 3 of the next 4 quarters over the next 12 months.
CounterHigh-growth medical device companies frequently face reimbursement headwinds and competitive entrants; sustaining 34% growth at scale becomes increasingly difficult.
The business scores a perfect 9/9 Piotroski F-Score and meets the Rule of 40 threshold at 43, while the moat score of 8.2/10 signals durable competitive advantages that support high returns on capital over time.
→StableQuality breakdown
- Expectation
- Gross margin holds above current levels and Piotroski F-Score stays at 8 or above over the next four reporting periods.
CounterA significant share of quality advantage derives from the Omnipod platform concentration, meaning any regulatory setback or competitive substitute directly impairs the moat.
Although MACD is showing improvement and RSI stands at 45, the stock remains below its 200-day moving average with the moving average slope at negative 8.0% per 30 days, meaning the technical recovery thesis requires a confirmed breakout above resistance to validate.
↓DeterioratingMomentum breakdown
- Expectation
- The stock rises above its 200-day moving average and momentum score rises above 5.0 within the next 6 months.
CounterDeath cross conditions combined with falling on-balance volume suggest that institutional sellers may continue to dominate price action, keeping momentum weak for an extended period.
Reliance on the single Omnipod product platform and sole-sourced components represents a structural risk where disruption to either the product line or the supply chain could materially impair revenue with limited near-term substitution options.
↓DeterioratingBear case
- Expectation
- The company discloses supply chain diversification progress or new product-line contributions exceed 10% of revenue within 12 months.
CounterPlatform concentration has not historically harmed Insulet; the Omnipod system's clinical differentiation and installed base create switching costs that offset concentration risk.
Per-dimension breakdown
Quality
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 7.7 |
| ROA | 6.5 |
| Gross margin | 10.0 |
| Op margin | 6.4 |
| Net margin | 5.2 |
| Current ratio | 8.5 |
| FCF quality | 6.2 |
| Moat | 8.2 |
| Rule of 40 | 7.3 |
| Piotroski F | 10.0 |
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
- ▸Rule of 40: 43 (pass)
- ▸Strong Piotroski F-Score: 9/9
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 34% YoY
Momentum
4.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 6.8 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 2.2 |
- ▸Volume distribution (falling OBV)
- ▸Below 200-MA, MA slope -10.0%/30d — confirmed downtrend
Sentiment
8.0/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 9.0 |
| Price target | 9.4 |
| erm sentiment | 4.7 |
- ▸Analyst upside: 46%
Insider
7.5/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.5 |
| holder change | 10.0 |
| notable moves | 7.0 |
- ▸Insider buying (low materiality) — $837,996 (0.007% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.8/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.2 |
| quality rank | 8.3 |
| growth rank | 8.5 |
- ▸Superior ROE vs peers
- ▸Industry growth leader
Technical
2.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 3.0 |
| support resistance | 3.7 |
| 52w position | 0.0 |
Risk (lower is worse)
5.4/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.2 |
| days to cover | 7.7 |
| volatility | 3.4 |
| put call | 3.7 |
| implied vol | 2.2 |
| max pain risk | 7.0 |
| beta | 6.6 |
| debt equity | 6.3 |
- ▸High IV: 67%
- ▸Concentration risks: 3 HIGH, 4 MED (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.5/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 10.0 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Perfect beat streak: 4Q
- ▸Earnings in 10 days
How the verdict was assembled
Engine trigger
Growth is cheap relative to earnings, but the technical setup has not yet produced a breakout above resistance (PEG 1.44, quality 7.6/10, growth 10.0/10).
Engine technical detail
verdict_path:
L4:PATH_C2_GARP_WAIT|ENTRY_STICKY:PRIOR_STILL_VIABLEPassed (6)
- ASYMMETRY:4.3>=1.5
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:4.1<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- EARNINGS_PROXIMITY:10d<=14d (soft)
Reward-to-Risk
4.31
Upside
+31.3%
Downside
7.3%
Sizing output
STARTER
SetupRecovery — Death cross but MACD improving, RSI 55
EdgeCatalyst-Driven — Earnings in 10d with 4/4 beat streak
SuitabilitySpeculative — Drawdown -54% (>40% off 52w high)
Investment implication
The C-path quality+growth combination triggered the STRONG_BUY_WAIT verdict: quality 7.6 and growth 10.0 both clear their thresholds, with asymmetric R:R of 4.31 supporting the read.
The strongest dimensions are Growth at 10.0, Sentiment at 8.0, and Quality at 7.6; the weakest are Technical at 2.2, Momentum at 4.1, and Risk (lower is worse) at 5.4. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 4.31 and an engine sizing output of STARTER.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Earnings Beat And Growth
Trip ifQuarterly EPS surprise falls below 0% in at least 2 of the next 4 quarters, signaling the beat streak has broken.
- P2Wide Moat Quality Profile
Trip ifPiotroski F-Score drops below 7 in any reporting period over the next 12 months.
- P3Technical Momentum Recovery
Trip ifThe 200-day moving average slope remains below negative 5% for more than 6 consecutive months.
- P4Concentration Risk Omnipod
Trip ifRevenue from the Omnipod platform exceeds 95% of total revenue for 2 or more consecutive quarters, increasing concentration above current levels.